These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25851544)

  • 1. Clinical-scale purification of pluripotent stem cell derivatives for cell-based therapies.
    Rodrigues GM; Rodrigues CA; Fernandes TG; Diogo MM; Cabral JM
    Biotechnol J; 2015 Aug; 10(8):1103-14. PubMed ID: 25851544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A massive suspension culture system with metabolic purification for human pluripotent stem cell-derived cardiomyocytes.
    Hemmi N; Tohyama S; Nakajima K; Kanazawa H; Suzuki T; Hattori F; Seki T; Kishino Y; Hirano A; Okada M; Tabei R; Ohno R; Fujita C; Haruna T; Yuasa S; Sano M; Fujita J; Fukuda K
    Stem Cells Transl Med; 2014 Dec; 3(12):1473-83. PubMed ID: 25355733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells.
    Ban K; Bae S; Yoon YS
    Theranostics; 2017; 7(7):2067-2077. PubMed ID: 28638487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of human pluripotent stem cells in clinical treatment.
    Simonson OE; Domogatskaya A; Volchkov P; Rodin S
    Ann Med; 2015; 47(5):370-80. PubMed ID: 26140342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Process engineering of human pluripotent stem cells for clinical application.
    Serra M; Brito C; Correia C; Alves PM
    Trends Biotechnol; 2012 Jun; 30(6):350-9. PubMed ID: 22541338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haematopoietic developmental potential of human pluripotent stem cell lines.
    Tesařová L; Simara P; Stejskal S; Koutná I
    Folia Biol (Praha); 2014; 60 Suppl 1():90-4. PubMed ID: 25369348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable propagation of human embryonic and induced pluripotent stem cells on decellularized human substrates.
    Abraham S; Sheridan SD; Miller B; Rao RR
    Biotechnol Prog; 2010; 26(4):1126-34. PubMed ID: 20730767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes.
    van den Heuvel NH; van Veen TA; Lim B; Jonsson MK
    J Mol Cell Cardiol; 2014 Feb; 67():12-25. PubMed ID: 24370890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of putative hematopoietic stem cells derived from human pluripotent stem cells.
    Hexum MK; Tian X; Kaufman DS
    Methods Mol Biol; 2011; 767():433-47. PubMed ID: 21822894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated platform for production and purification of human pluripotent stem cell-derived neural precursors.
    Rodrigues GM; Matos AF; Fernandes TG; Rodrigues CA; Peitz M; Haupt S; Diogo MM; Brüstle O; Cabral JM
    Stem Cell Rev Rep; 2014 Apr; 10(2):151-61. PubMed ID: 24221956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards.
    Martin RM; Fowler JL; Cromer MK; Lesch BJ; Ponce E; Uchida N; Nishimura T; Porteus MH; Loh KM
    Nat Commun; 2020 Jun; 11(1):2713. PubMed ID: 32483127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of an NAD⁺ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells.
    Kropp EM; Oleson BJ; Broniowska KA; Bhattacharya S; Chadwick AC; Diers AR; Hu Q; Sahoo D; Hogg N; Boheler KR; Corbett JA; Gundry RL
    Stem Cells Transl Med; 2015 May; 4(5):483-93. PubMed ID: 25834119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and cultivation of naive-like human pluripotent stem cells based on HERVH expression.
    Wang J; Singh M; Sun C; Besser D; Prigione A; Ivics Z; Hurst LD; Izsvák Z
    Nat Protoc; 2016 Feb; 11(2):327-46. PubMed ID: 26797457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotyping of Live Human Pluripotent Stem Cells by Flow Cytometry.
    Riordon DR; Boheler KR
    Methods Mol Biol; 2018; 1722():127-149. PubMed ID: 29264803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering the human pluripotent stem cell microenvironment to direct cell fate.
    Hazeltine LB; Selekman JA; Palecek SP
    Biotechnol Adv; 2013 Nov; 31(7):1002-19. PubMed ID: 23510904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Culturing human pluripotent stem cells for regenerative medicine.
    Ozawa H; Matsumoto T; Nakagawa M
    Expert Opin Biol Ther; 2023; 23(6):479-489. PubMed ID: 37345510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical translation of pluripotent stem cell-based therapies: successes and challenges.
    Christiansen JR; Kirkeby A
    Development; 2024 Apr; 151(7):. PubMed ID: 38564308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Tumorigenic Potential of Human Pluripotent Stem Cells.
    Lezmi E; Benvenisty N
    Stem Cells Transl Med; 2022 Aug; 11(8):791-796. PubMed ID: 35679163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New medium used in the differentiation of human pluripotent stem cells to retinal cells is comparable to fetal human eye tissue.
    Wang X; Xiong K; Lin C; Lv L; Chen J; Xu C; Wang S; Gu D; Zheng H; Yu H; Li Y; Xiao H; Zhou G
    Biomaterials; 2015 Jun; 53():40-9. PubMed ID: 25890705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.